Stockscreener 앱 받기
10.88
6.61%
-0.77
시간 외 거래:
11.09
0.21
+1.93%
전일 마감가:
$11.65
열려 있는:
$11.67
하루 거래량:
80,376
Relative Volume:
0.06
시가총액:
$98.03M
수익:
$23.14M
순이익/손실:
$-9.47M
주가수익비율:
-12.33
EPS:
-0.8827
순현금흐름:
$-25.88M
1주 성능:
-2.60%
1개월 성능:
+9.68%
6개월 성능:
-25.33%
1년 성능:
+28.53%
1일 변동 폭
$10.74
$11.86
1주일 범위
$10.74
$12.00
52주 변동 폭
$3.92
$19.14
아타라 Stock (ATRA) Company Profile
명칭
Atara Biotherapeutics Inc
전화
805-623-4211
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
10.88 | 103.44M | 23.14M | -9.47M | -25.88M | -0.8827 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
아타라 Stock (ATRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-20 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-07-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-07-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-05-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 개시 | Evercore ISI | Outperform |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-23 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-09-27 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-09-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-06-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-05-23 | 개시 | Stifel | Buy |
| 2019-01-23 | 개시 | Mizuho | Buy |
| 2018-04-10 | 개시 | JP Morgan | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2018-03-05 | 재확인 | Jefferies | Buy |
| 2018-02-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-01-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
아타라 주식(ATRA)의 최신 뉴스
Discipline and Rules-Based Execution in ATRA Response - Stock Traders Daily
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - ACCESS Newswire
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - ACCESS Newswire
Atara Biotherapeutics Inc Actuals & Estimates (GETTEX:AT20) - TradingView
Atara Biotherapeutics Inc Actuals & Estimates (SWB:AT20) - TradingView
ATRA News | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Atara Biotherapeutics (NASDAQ: ATRA) appoints CRCFO consultant as interim CFO - Stock Titan
Atara Biotherapeutics Inc Actuals & Estimates (NASDAQ:ATRA) - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
ATRA Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Atara Biotherapeutics Inc (ATRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Institutional Confidence - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Behavioral Patterns of ATRA and Institutional Flows - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - ACCESS Newswire
Atara Biotherapeutics Inc (ATRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atara Biotherapeutics Inc (ATRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atara Biotherapeutics Inc (ATRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atara Biotherapeutics Inc (ATRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atara Biotherapeutics Inc (ATRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atara Biotherapeutics Inc (ATRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atara Biotherapeutics Inc (ATRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - ACCESS Newswire
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cherry Brian N - Moomoo
Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units - Stock Titan
Atara Biotherapeutics (NASDAQ: ATRA) director reports 38,320-share common stock holding - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Atara Biotherapeutics Adds Independent Director to Board - The Globe and Mail
Atara Biotherapeutics appoints Brian Cherry to board By Investing.com - Investing.com Australia
Atara Biotherapeutics appoints Brian Cherry to board - Investing.com
New Atara (NASDAQ: ATRA) director and 2026 shareholder vote outcomes - Stock Titan
Atara Biotherapeutics Announces Changes to Its Board of Directors - The Joplin Globe
symbol__ Stock Quote Price and Forecast - CNN
Atara Biotherapeutics (ATRA) director granted 12,000 restricted stock units - Stock Titan
Atara Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fust Matthew K - Moomoo
Atara Biotherapeutics (ATRA) director receives 12,000-share RSU grant - Stock Titan
Atara Biotherapeutics (ATRA) awards director 12,000 RSUs and reports fund holdings - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ATRA: All proposals, including director elections and equity plan amendment, were approved - TradingView
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
2026-06-09 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse
(ATRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
2026-06-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse
ATRA stock shoots up 82% in a month: Here's what you should know - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
아타라 (ATRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아타라 주식 (ATRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
May 18 '26 |
Sale |
9.13 |
2,414 |
22,036 |
49,636 |
0.05%
0.74%
자본화:
|
볼륨(24시간):